Is FibroBiologics, Inc. (FBLG) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.2% / 30% | 16.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 8.2% / 33% | 16.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 25.1% / 33% | 50.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 8.2% / 33% | 16.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 25.1% / 33% | 50.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -419.4% | |
| Return on Assets (ROA) | -79.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$17M |
| Total Debt | $2M |
| Debt-to-Equity | 39.1 |
| Current Ratio | 3.6 |
| Total Assets | $10M |
Price & Trading
| Last Close | $0.22 |
| 50-Day MA | $6.02 |
| 200-Day MA | $8.55 |
| Avg Volume | 1.7M |
| Beta | -0.7 |
|
52-Week Range
$0.19
| |
About FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is FibroBiologics, Inc. (FBLG) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), FibroBiologics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is FibroBiologics, Inc.'s debt ratio?
FibroBiologics, Inc.'s debt ratio is 8.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.1%.
What are FibroBiologics, Inc.'s key financial metrics?
FibroBiologics, Inc. has a market capitalization of $669,982. Return on equity stands at -419.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.